Kourosh Rezania

Dr. Kourosh Rezania

Department of Neurology, University of Chicago, Chicago, USA
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LDLaura Dresser
Laura Dresser
RWRichard Wlodarski
Richard Wlodarski
KRKourosh Rezania
Kourosh Rezania
BSBetty Soliven
Betty Soliven
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases per million person-years, and the prevalence rate ranges from 150 to 200 cases per million. MG is considered a classic example of antibody-mediated autoimmune disease. Most patients with MG have autoantibodies against the acetylcholine receptors (AChRs). Less commonly identified autoantibodies include those targeted to muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (Lrp4), and agrin. These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane. The core clinical manifestation of MG is fatigable muscle weakness, which may affect ocular, bulbar, respiratory and limb muscles. Clinical manifestations vary according to the type of autoantibody, and whether a thymoma is present.

14 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAMohammed K. Alhaidar
Mohammed K. Alhaidar
SASumayyah Abumurad
Sumayyah Abumurad
BSBetty Soliven
Betty Soliven
KRKourosh Rezania
Kourosh Rezania
Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with a high mortality rate in the early 20th century to a treatable condition with a large proportion of patients attaining very good disease control. This review summarizes the current treatment options for MG, including non-immunosuppressive and immunosuppressive treatments, as well as thymectomy and targeted immunomodulatory drugs.

Verified
Journal Article
Open access
PDF file
SSShuja Sheikh
Shuja Sheikh
UAUsman Alvi
Usman Alvi
BSBetty Soliven
Betty Soliven
KRKourosh Rezania
Kourosh Rezania
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder which is characterized by presence of antibodies against acetylcholine receptors (AChRs) or other proteins of the postsynaptic membrane resulting in damage to postsynaptic membrane, decreased number of AChRs or blocking of the receptors by autoantibodies. A number of drugs such as immune checkpoint inhibitors, penicillamine, tyrosine kinase inhibitors and interferons may induce de novo MG by altering the immune homeostasis mechanisms which prevent emergence of autoimmune diseases such as MG. Other drugs, especially certain antibiotics, antiarrhythmics, anesthetics and neuromuscular blockers, have deleterious effects on neuromuscular transmission, resulting in increased weakness in MG or MG-like symptoms in patients who do not have MG, with the latter usually being under medical circumstances such as kidney failure. This review summarizes the drugs which can cause de novo MG, MG exacerbation or MG-like symptoms in nonmyasthenic patients.

1 September 2003 in Amyotrophic Lateral Sclerosis
Verified
Journal Article
Closed access
KRKourosh Rezania
Kourosh Rezania
JYJianhua Yan
Jianhua Yan
LDLisa Dellefave
Lisa Dellefave
HDHan‐Xiang Deng
Han‐Xiang Deng
NSNailah Siddique
Nailah Siddique
RRRaymond P Roos
Raymond P Roos
We present three members of a pedigree with familial amyotrophic lateral sclerosis (FALS) who have a rare mutation in exon 4 of Cu/Zn superoxide dismutase (SOD1) codon position 89, converting alanine to valine. This mutation was associated with incomplete penetrance and variable age of onset. The onset of the disease was late in two of our patients and early in the other. Two of our patients had symptoms and/or signs of an associated painful sensory neuropathy. The incomplete disease penetrance seen with this mutation (and others reported in the literature) emphasizes the potential value for obtaining an SOD1 genotype in patients with ALS, even if there is no apparent family history.

23 November 2016 in Neurological Research
Verified
Journal Article
Closed access
MKManisha Kak
Manisha Kak
NINaoum P. Issa
Naoum P. Issa
RRRaymond P. Roos
Raymond P. Roos
BSBobbie Jean Sweitzer
Bobbie Jean Sweitzer
OGOri Gottlieb
Ori Gottlieb
KRKourosh Rezania
Kourosh Rezania
Objectives: To evaluate the safety and effect on survival of insertion of a gastrostomy tube (G-tube) in patients with amyotrophic lateral sclerosis (ALS) who have upright forced vital capacity (uFVC) ≤ 50% predicted. Current guidelines, which are based on higher rates of post-procedure complications in ALS patients with advanced respiratory dysfunction, have led to a recommendation to perform G-tube insertion before the FVC drops to <50% predicted, even when the patient has no significant dysphagia. Methods: We assessed 41 ALS patients who received a G-tube, mostly by insertion of a percutaneous endoscopic gastrostomy (PEG) tube by a dedicated team that included a gastroenterologist and one of two anesthesiologists using Monitored Anesthesia Care with deep sedation, and 61 patients who did not receive a G-tube. uFVC was ≤50% predicted in 12 of 41 patients who received a G-tube and in 18 of 61 who did not. Results: The procedure was safe regardless of FVC status, with low rates of post-operative complications in both low and high FVC groups. There was no survival benefit for patients who received a G-tube when compared with those who did not. Discussion: PEG insertion is safe in ALS patients with significant respiratory muscle weakness when performed by a dedicated team, which suggests that the recommendation for G-tube placement should not be based on the patient’s respiratory status.

3 February 2017 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
NINaoum P. Issa
Naoum P. Issa
SFSamuel Frank
Samuel Frank
RRRaymond P. Roos
Raymond P. Roos
BSBetty Soliven
Betty Soliven
VTVernon L. Towle
Vernon L. Towle
KRKourosh Rezania
Kourosh Rezania